{"transactions":[{"id":1608718,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-01T16:40:02.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":2119,"price":6.27,"value":13286.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024."}],"balance_after":460621,"source":{"system":"sec-edgar","filing":"0000950170-24-023945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000095017024023945/ownership.xml","form_type":"4"}},{"id":1611114,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-29T16:44:24.000Z","date":"2024-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":3154,"price":6.44,"value":20311.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The disposition reported on this Form 4 represents shares of Common Stock withheld by the Issuer to cover the tax liability upon the vesting of PSUs on February 27, 2024 and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":462740,"source":{"system":"sec-edgar","filing":"0000950170-24-023198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000095017024023198/ownership.xml","form_type":"4"}},{"id":1611113,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-29T16:44:24.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":12950,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock received upon vesting of performance stock units (\"PSUs\") that were granted on February 2, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock received upon vesting of performance stock units (\"PSUs\") that were granted on February 2, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the transfer of 88,181 shares of Common Stock pursuant to a Rule 16a-12 transaction."}],"balance_after":465894,"source":{"system":"sec-edgar","filing":"0000950170-24-023198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000095017024023198/ownership.xml","form_type":"4"}},{"id":1683324,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-09T17:00:02.000Z","date":"2024-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":4322,"price":5.13,"value":22171.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on January 5, 2024."}],"balance_after":541125,"source":{"system":"sec-edgar","filing":"0000950170-24-003397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000095017024003397/ownership.xml","form_type":"4"}},{"id":1750716,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-11-03T16:39:26.000Z","date":"2023-11-02","kind":"sale","planned":true,"acquired":false,"shares":10694,"price":13.87,"value":148325.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive."}],"balance_after":545447,"source":{"system":"sec-edgar","filing":"0001209191-23-054333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123054333/doc4.xml","form_type":"4"}},{"id":1750715,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-11-03T16:39:26.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":10925,"price":13.82,"value":150983.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":556141,"source":{"system":"sec-edgar","filing":"0001209191-23-054333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123054333/doc4.xml","form_type":"4"}},{"id":1766054,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-04T17:07:25.000Z","date":"2023-10-03","kind":"sale","planned":true,"acquired":false,"shares":710,"price":15.11,"value":10728.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.18 inclusive."}],"balance_after":567066,"source":{"system":"sec-edgar","filing":"0001209191-23-052030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123052030/doc4.xml","form_type":"4"}},{"id":1766053,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-04T17:07:25.000Z","date":"2023-10-03","kind":"sale","planned":true,"acquired":false,"shares":10024,"price":14.41,"value":144445.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.09 to $15.05 inclusive."}],"balance_after":567776,"source":{"system":"sec-edgar","filing":"0001209191-23-052030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123052030/doc4.xml","form_type":"4"}},{"id":1766052,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-10-04T17:07:25.000Z","date":"2023-10-02","kind":"sale","planned":true,"acquired":false,"shares":9511,"price":15.23,"value":144852.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.035 to $15.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4)."}],"balance_after":577800,"source":{"system":"sec-edgar","filing":"0001209191-23-052030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123052030/doc4.xml","form_type":"4"}},{"id":1887760,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-18T17:22:57.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":19.98,"value":299700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.7454 to $20.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This report reflects an adjustment to the Reporting Person's direct holdings to exclude shares incorrectly included in prior reports as directly held and to reflect such shares as held indirectly through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the \"Trust\")."}],"balance_after":587311,"source":{"system":"sec-edgar","filing":"0001209191-23-030725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123030725/doc4.xml","form_type":"4"}},{"id":1894297,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-15T20:34:29.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":200,"price":21.52,"value":4304.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.525 inclusive."}],"balance_after":1594934,"source":{"system":"sec-edgar","filing":"0001209191-23-029625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123029625/doc4.xml","form_type":"4"}},{"id":1894296,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-15T20:34:29.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":14800,"price":21.06,"value":311688.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.4867 to $21.43 inclusive."}],"balance_after":1595134,"source":{"system":"sec-edgar","filing":"0001209191-23-029625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123029625/doc4.xml","form_type":"4"}},{"id":1894295,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-15T20:34:29.000Z","date":"2023-05-12","kind":"sale","planned":false,"acquired":false,"shares":11869,"price":20.42,"value":242364.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.745 inclusive."}],"balance_after":1609934,"source":{"system":"sec-edgar","filing":"0001209191-23-029625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123029625/doc4.xml","form_type":"4"}},{"id":1894294,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-15T20:34:29.000Z","date":"2023-05-12","kind":"sale","planned":false,"acquired":false,"shares":3131,"price":19.69,"value":61649.39,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.11 inclusive."}],"balance_after":1621803,"source":{"system":"sec-edgar","filing":"0001209191-23-029625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123029625/doc4.xml","form_type":"4"}},{"id":1894293,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-15T20:34:29.000Z","date":"2023-05-11","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":20.71,"value":310650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5)."}],"balance_after":1624934,"source":{"system":"sec-edgar","filing":"0001209191-23-029625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123029625/doc4.xml","form_type":"4"}},{"id":1981727,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-02T16:18:53.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":70900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of March 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":1639934,"source":{"system":"sec-edgar","filing":"0001209191-23-014646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123014646/doc4.xml","form_type":"4"}},{"id":1981726,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-03-02T16:18:53.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":3113,"price":28,"value":87164.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":1569034,"source":{"system":"sec-edgar","filing":"0001209191-23-014646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123014646/doc4.xml","form_type":"4"}},{"id":2048062,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-01-24T18:13:24.000Z","date":"2023-01-23","kind":"tax_withholding","acquired":false,"shares":3732,"price":33.64,"value":125544.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":1572147,"source":{"system":"sec-edgar","filing":"0001209191-23-004680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123004680/doc4.xml","form_type":"4"}},{"id":2059429,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-01-09T16:33:24.000Z","date":"2023-01-05","kind":"tax_withholding","acquired":false,"shares":3827,"price":29.26,"value":111978.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":1575879,"source":{"system":"sec-edgar","filing":"0001209191-23-002566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919123002566/doc4.xml","form_type":"4"}},{"id":2362979,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-02T18:02:00.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":34800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of February 28, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":1579706,"source":{"system":"sec-edgar","filing":"0001209191-22-015009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919122015009/doc4.xml","form_type":"4"}},{"id":2759555,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-05T16:54:43.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":31201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.78,"expiration_date":"2021-05-02","underlying":"Common Stock","underlying_shares":31201},"source":{"system":"sec-edgar","filing":"0001209191-21-025187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919121025187/doc4.xml","form_type":"4"}},{"id":2759554,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-04-05T16:54:43.000Z","date":"2021-04-01","kind":"tax_withholding","acquired":false,"shares":16278,"price":41.87,"value":681559.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to pay exercise price and to satisfy withholding tax obligations."}],"balance_after":1544906,"source":{"system":"sec-edgar","filing":"0001209191-21-025187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919121025187/doc4.xml","form_type":"4"}},{"id":2759553,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-04-05T16:54:43.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":31201,"price":8.78,"value":273944.78,"ownership":{"direct":true},"balance_after":1561184,"source":{"system":"sec-edgar","filing":"0001209191-21-025187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919121025187/doc4.xml","form_type":"4"}},{"id":2759552,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-04-05T16:54:43.000Z","date":"2021-02-23","kind":"gift","acquired":false,"shares":16340,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1529983,"source":{"system":"sec-edgar","filing":"0001209191-21-025187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919121025187/doc4.xml","form_type":"4"}},{"id":2896428,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-01-26T18:31:16.000Z","date":"2021-01-23","kind":"tax_withholding","acquired":false,"shares":4631,"price":47.7,"value":220898.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to satisfy withholding tax obligations."}],"balance_after":1546323,"source":{"system":"sec-edgar","filing":"0001209191-21-005495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919121005495/doc4.xml","form_type":"4"}},{"id":3301779,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2020-01-27T16:17:16.000Z","date":"2020-01-23","kind":"tax_withholding","acquired":false,"shares":7548,"price":57.98,"value":437633.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to satisfy withholding tax obligations."}],"balance_after":1550954,"source":{"system":"sec-edgar","filing":"0001209191-20-004990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919120004990/doc4.xml","form_type":"4"}},{"id":3317014,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-07T18:29:04.000Z","date":"2020-01-05","kind":"grant","acquired":true,"shares":145700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 5, 2021, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":145700,"derivative":{"exercise_price":59.795,"expiration_date":"2030-01-04","underlying":"Common Stock","underlying_shares":145700},"source":{"system":"sec-edgar","filing":"0001209191-20-002360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919120002360/doc4.xml","form_type":"4"}},{"id":3317013,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2020-01-07T18:29:04.000Z","date":"2020-01-05","kind":"grant","acquired":true,"shares":58300,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 5, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1558502,"source":{"system":"sec-edgar","filing":"0001209191-20-002360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919120002360/doc4.xml","form_type":"4"}},{"id":3323847,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T22:11:54.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":50562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date."}],"balance_after":50562,"derivative":{"exercise_price":4.72,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":50562},"source":{"system":"sec-edgar","filing":"0001209191-20-001186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001186/doc4.xml","form_type":"4"}},{"id":3350253,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-12-06T12:13:39.000Z","date":"2019-12-04","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date."}],"balance_after":250000,"derivative":{"exercise_price":0.418,"exercise_date":"2019-12-04","expiration_date":"2026-12-04","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-19-070376","document":"tm1923941d5_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000110465919070376/tm1923941d5_form4.xml","form_type":"4"}},{"id":3566757,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Commn Stock","published_at":"2019-04-03T16:33:45.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":24975,"price":50.15,"value":1252496.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1500202,"source":{"system":"sec-edgar","filing":"0001209191-19-023147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119023147/doc4.xml","form_type":"4"}},{"id":3621052,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-03-04T16:31:48.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":12428,"price":51.81,"value":643894.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.3201 to $52.2003 inclusive."}],"balance_after":1525177,"source":{"system":"sec-edgar","filing":"0001209191-19-015645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119015645/doc4.xml","form_type":"4"}},{"id":3621051,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-03-04T16:31:48.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":12000,"price":50.51,"value":606120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.1615 to $51.0577 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":1537605,"source":{"system":"sec-edgar","filing":"0001209191-19-015645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119015645/doc4.xml","form_type":"4"}},{"id":3678537,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-02-04T20:04:57.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":900,"price":42.3,"value":38070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.49 inclusive."}],"balance_after":1549605,"source":{"system":"sec-edgar","filing":"0001209191-19-007134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119007134/doc4.xml","form_type":"4"}},{"id":3678536,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-02-04T20:04:57.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":29185,"price":41.52,"value":1211761.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":1550505,"source":{"system":"sec-edgar","filing":"0001209191-19-007134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119007134/doc4.xml","form_type":"4"}},{"id":3687459,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-25T20:07:28.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":137200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 23, 2020, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":137200,"derivative":{"exercise_price":42.4,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":137200},"source":{"system":"sec-edgar","filing":"0001209191-19-005447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119005447/doc4.xml","form_type":"4"}},{"id":3687458,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-25T20:07:28.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":61300,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\").  The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 23, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1579690,"source":{"system":"sec-edgar","filing":"0001209191-19-005447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119005447/doc4.xml","form_type":"4"}},{"id":3706146,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-04T21:22:24.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":302,"price":40.57,"value":12252.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.36 to $40.78 inclusive."}],"balance_after":1518390,"source":{"system":"sec-edgar","filing":"0001209191-19-002391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/doc4.xml","form_type":"4"}},{"id":3706145,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-04T21:22:24.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":5670,"price":39.7,"value":225099.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.46 to $40.35 inclusive."}],"balance_after":1518692,"source":{"system":"sec-edgar","filing":"0001209191-19-002391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/doc4.xml","form_type":"4"}},{"id":3706144,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-04T21:22:24.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":10597,"price":39.04,"value":413706.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.46 to $39.04 inclusive."}],"balance_after":1524362,"source":{"system":"sec-edgar","filing":"0001209191-19-002391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/doc4.xml","form_type":"4"}},{"id":3706143,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-04T21:22:24.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":8500,"price":40.03,"value":340255.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.63 to $40.53 inclusive."}],"balance_after":1534959,"source":{"system":"sec-edgar","filing":"0001209191-19-002391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/doc4.xml","form_type":"4"}},{"id":3706142,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2019-01-04T21:22:24.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":6500,"price":39.3,"value":255450.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.63 to $39.615 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4."}],"balance_after":1543459,"source":{"system":"sec-edgar","filing":"0001209191-19-002391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/doc4.xml","form_type":"4"}},{"id":3714469,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-03T02:18:22.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":126700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"126,700 options vest on 12/31/2019."}],"balance_after":126700,"derivative":{"exercise_price":1.87,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":126700},"source":{"system":"sec-edgar","filing":"0001209191-19-000590","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919119000590/doc4.xml","form_type":"4"}},{"id":3740326,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2018-12-07T22:01:12.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":79500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options will vest monthly on a pro rata basis over 36 consecutive months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest monthly on a pro rata basis over 36 consecutive months."}],"balance_after":79500,"derivative":{"exercise_price":0.6895,"exercise_date":"2018-12-06","expiration_date":"2025-12-06","underlying":"Common Stock","underlying_shares":79500},"source":{"system":"sec-edgar","filing":"0001144204-18-063625","document":"tv508642_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420418063625/tv508642_4.xml","form_type":"4"}},{"id":3877197,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-03T17:09:28.000Z","date":"2018-06-28","kind":"exercise","acquired":false,"shares":124804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on April 2, 2010 and the remainder vested in equal monthly installments over a period of three years ending April 2, 2013."}],"balance_after":0,"derivative":{"exercise_price":4.04,"expiration_date":"2019-04-02","underlying":"Common Stock","underlying_shares":124804},"source":{"system":"sec-edgar","filing":"0001209191-18-041189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118041189/doc4.xml","form_type":"4"}},{"id":3877196,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2018-07-03T17:09:28.000Z","date":"2018-06-28","kind":"exercise","acquired":true,"shares":124804,"price":4.04,"value":504208.16,"ownership":{"direct":true},"balance_after":1549959,"source":{"system":"sec-edgar","filing":"0001209191-18-041189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118041189/doc4.xml","form_type":"4"}},{"id":3974957,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-04-03T17:05:34.000Z","date":"2018-03-30","kind":"exercise","acquired":false,"shares":113104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.04,"expiration_date":"2018-10-02","underlying":"Common Stock","underlying_shares":113104},"source":{"system":"sec-edgar","filing":"0001209191-18-023136","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118023136/doc4.xml","form_type":"4"}},{"id":3974956,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2018-04-03T17:05:34.000Z","date":"2018-03-30","kind":"tax_withholding","acquired":false,"shares":57895,"price":52.69,"value":3050487.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to pay exercise price and to satisfy withholding tax obligations."}],"balance_after":1425155,"source":{"system":"sec-edgar","filing":"0001209191-18-023136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118023136/doc4.xml","form_type":"4"}},{"id":3974955,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2018-04-03T17:05:34.000Z","date":"2018-03-30","kind":"exercise","acquired":true,"shares":113104,"price":4.04,"value":456940.16,"ownership":{"direct":true},"balance_after":1483050,"source":{"system":"sec-edgar","filing":"0001209191-18-023136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118023136/doc4.xml","form_type":"4"}},{"id":4103640,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Peformance Stock Unit","published_at":"2018-01-09T17:50:50.000Z","date":"2018-01-07","kind":"grant","acquired":true,"shares":189000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the maximum number of shares issuable under this award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares issuable in respect of such PSUs shall vest on the three-year anniversary of January 1, 2018 (such three-year anniversary, the \"Vesting Date\"), based on the extent to which the following stock price hurdles are achieved for 30 consecutive trading days on or prior to the Vesting Date.  If the Issuer's stock price reaches or surpasses $85.92, $110.00, $120.00 or $134.25, then 63,000, 126,000, 157,500 or 189,000 PSUs will vest, respectively.  The number of shares issuable in respect of such PSUs vested on the Vesting Date will be determined by the highest Issuer stock price hurdle achieved.  This vesting is subject to the Reporting Person's continuous service with the Issuer as of the Vesting Date."}],"balance_after":189000,"derivative":{"expiration_date":"2021-01-01","underlying":"Common Stock","underlying_shares":189000},"source":{"system":"sec-edgar","filing":"0001209191-18-003005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118003005/doc4.xml","form_type":"4"}},{"id":4103639,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-09T17:50:50.000Z","date":"2018-01-07","kind":"grant","acquired":true,"shares":157000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 7, 2019, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":157000,"derivative":{"exercise_price":59.14,"expiration_date":"2028-01-07","underlying":"Common Stock","underlying_shares":157000},"source":{"system":"sec-edgar","filing":"0001209191-18-003005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919118003005/doc4.xml","form_type":"4"}},{"id":4113048,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (Right to Buy)","published_at":"2018-01-03T22:00:50.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,000 shares shall vest on 12/29/2018."}],"balance_after":25000,"derivative":{"exercise_price":4.14,"expiration_date":"2027-12-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-001017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919118001017/doc4.xml","form_type":"4"}},{"id":4124326,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2017-12-21T22:18:35.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These stock options vest in full on the one year anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in full on the one year anniversary of the grant date."}],"balance_after":200000,"derivative":{"exercise_price":0.52,"exercise_date":"2018-12-20","expiration_date":"2024-12-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001144204-17-064824","document":"tv481800_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420417064824/tv481800_4.xml","form_type":"4"}},{"id":4497046,"issuer":{"id":85958,"kind":"organization","name":"EAGLE PHARMACEUTICALS, INC.","symbol":"EGRX"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-06T17:10:02.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":200900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2018, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":200900,"derivative":{"exercise_price":84.92,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":200900},"source":{"system":"sec-edgar","filing":"0001209191-17-002689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827871/000120919117002689/doc4.xml","form_type":"4"}},{"id":4503627,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-04T21:37:42.000Z","date":"2016-12-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,000 shares shall vest on 12/30/2017."}],"balance_after":25000,"derivative":{"exercise_price":5.35,"expiration_date":"2026-12-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-000968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919117000968/doc4.xml","form_type":"4"}},{"id":4536023,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2016-12-02T22:07:42.000Z","date":"2016-11-30","kind":"grant","acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date."}],"balance_after":168750,"derivative":{"exercise_price":0.8,"exercise_date":"2016-11-30","expiration_date":"2023-11-29","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001144204-16-137744","document":"v454264_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420416137744/v454264_4.xml","form_type":"4"}},{"id":4549417,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrant","published_at":"2016-11-18T16:12:14.000Z","date":"2016-11-18","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00."}],"balance_after":300000,"derivative":{"exercise_price":1.72,"exercise_date":"2016-11-18","expiration_date":"2017-12-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001144204-16-135295","document":"v453318_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420416135295/v453318_4.xml","form_type":"4"}},{"id":4549416,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrant","published_at":"2016-11-18T16:12:14.000Z","date":"2016-11-18","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00."}],"balance_after":300000,"derivative":{"exercise_price":1.43,"exercise_date":"2016-11-18","expiration_date":"2020-11-18","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001144204-16-135295","document":"v453318_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420416135295/v453318_4.xml","form_type":"4"}},{"id":4549415,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":93687,"kind":"person","name":"Tarriff Scott","position":1,"cik":"0001469124","reported_name":"Tarriff Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-18T16:12:14.000Z","date":"2016-11-18","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were sold together with the Series A Warrant and the Series B Warrant. The purchase price for each share of common stock and accompanying warrant was $1.00."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001144204-16-135295","document":"v453318_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000114420416135295/v453318_4.xml","form_type":"4"}}]}